In fiscal year 2025, Humana Inc. reported robust revenue growth driven by its combined Insurance and CenterWell segments, reflecting focused Medicare Advantage and Medicaid portfolios alongside expanded pharmacy and primary care operations. However, operating income growth moderated to 5.5% while net income declined slightly due to rising medical costs and actuarial pricing complexities. The CenterWell segment’s progress offsets some membership declines in core insurance lines. Capital returns are constrained amid diminished operating cash flows and reduced share repurchases, highlighting tightening financial flexibility. Looking ahead, Humana’s investments in clinical programs aim to sustain growth but are tempered by ongoing regulatory pressures including Medicare Star Ratings reviews and reimbursement uncertainties.